Relacorilant

未知生产厂商

Relacorilant is under investigation in clinical trial NCT02804750 (Study to Evaluate CORT125134 in Patients With Cushing's Syndrome).

生成 AI 研报

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Relacorilant is under investigation in clinical trial NCT02804750 (Study to Evaluate CORT125134 in Patients With Cushing's Syndrome).

技术标识符

化学式: C₂₇H₂₂F₄N₆O₃S
CAS 编号: 1496510-51-0
UNII ID: 2158753C7E

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

THERAPEUTIC USES OF RELACORILANT, A HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATOR
EP 3927345 A4申请人: CORCEPT THERAPEUTICS INC优先权: 2019
CN
EP
US
WO
12 件公开
PHARMACEUTICAL FORMULATIONS CONTAINING RELACORILANT, A HETEROARYL-KETONE FUSED AZADECALIN COMPOUND
EP 3897589 B1申请人: CORCEPT THERAPEUTICS INC优先权: 2018
CN
EP
US
WO
10 件公开
METHODS FOR SHRINKING PITUITARY TUMORS
EP 3876936 A4申请人: CORCEPT THERAPEUTICS INC优先权: 2018
CN
EP
US
WO
9 件公开
CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND PACLITAXEL, A DUAL SUBSTRATE OF CYP2C8 AND CYP3A4
EP 4157276 A4申请人: CORCEPT THERAPEUTICS INC优先权: 2020
EP
US
WO
9 件公开
METHOD OF NORMALIZING THE NEUTROPHIL TO LYMPHOCYTE RATIO IN CANCER PATIENTS WITH A SELECTIVE GLUCOCORTICOID RECEPTOR ANTAGONIST
EP 4045045 A1申请人: CORCEPT THERAPEUTICS INC优先权: 2019
EP
US
WO
5 件公开
CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND CYP2C9 SUBSTRATES
EP 4157274 A4申请人: CORCEPT THERAPEUTICS INC优先权: 2020
EP
US
WO
4 件公开
METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT
EP 4525870 A4申请人: CORCEPT THERAPEUTICS INC优先权: 2022
EP
US
WO
4 件公开
METHODS OF ASSESSING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATION AND OF IDENTIFYING AND TREATING PATIENTS LIKELY TO BENEFIT FROM GLUCOCORTICOID RECEPTOR MODULATION
EP 4581171 A4申请人: CORCEPT THERAPEUTICS INC优先权: 2022
EP
US
WO
3 件公开
TREATMENTS FOR CUSHING'S SYNDROME THAT DO NOT SIGNIFICANTLY AFFECT CARDIAC RHYTHMS
EP 4626428 A1申请人: CORCEPT THERAPEUTICS INC优先权: 2022
EP
US
WO
3 件公开
METHODS FOR TREATING ADRENAL GLAND TUMORS
EP 4716536 A1申请人: CORCEPT THERAPEUTICS INC优先权: 2023
EP
US
WO
3 件公开

药物